{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:56:54Z","timestamp":1790848614739,"version":"4.1.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.amjmed.2026.06.038","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:05:44Z","timestamp":1783177544000},"page":"1416-1418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mineralocorticoid antagonists for post-MI HFpEF: Plausible biology meets low residual risk?"],"prefix":"10.1016","volume":"139","author":[{"suffix":"Jr","given":"Steven C.","family":"Ajluni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0924-3135","authenticated-orcid":false,"given":"Scott L.","family":"Hummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2026.06.038_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2026.03.049","article-title":"Efficacy of spironolactone in patients with heart failure with preserved ejection fraction following acute myocardial infarction: a multicenter retrospective cohort analysis","author":"Zhu","year":"2026","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2026.06.038_bib0002","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1139\/cjpp-2020-0276","article-title":"The role of aldosterone inhibitors in cardiac ischemia-reperfusion injury","volume":"99","author":"Dragasevic","year":"2021","journal-title":"Can J Physiol Pharmacol"},{"issue":"5","key":"10.1016\/j.amjmed.2026.06.038_bib0003","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.amjcard.2010.04.012","article-title":"Relation between infarct size in ST-segment elevation myocardial infarction treated successfully by percutaneous coronary intervention and left ventricular ejection fraction three months after the infarct","volume":"106","author":"Pride","year":"2010","journal-title":"Am J Cardiol"},{"issue":"14","key":"10.1016\/j.amjmed.2026.06.038_bib0004","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.amjmed.2026.06.038_bib0005","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","article-title":"Early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial","volume":"67","author":"Beygui","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.amjmed.2026.06.038_bib0006","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1056\/NEJMoa2405923","article-title":"Routine spironolactone in acute myocardial infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2026.06.038_bib0007","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1186\/s12872-025-04969-1","article-title":"A predictive model for heart failure with preserved ejection fraction following acute myocardial infarction: the HFpEF-AMI score","volume":"25","author":"Wu","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"issue":"5","key":"10.1016\/j.amjmed.2026.06.038_bib0008","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ejhf.3225","article-title":"Incidence and predictors of heart failure with reduced and preserved ejection fraction after ST-elevation myocardial infarction in the contemporary era of early percutaneous coronary intervention","volume":"26","author":"Lenselink","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.amjmed.2026.06.038_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018331","article-title":"An electronic health records cohort study on heart failure following myocardial infarction in England: incidence and predictors","volume":"8","author":"Gho","year":"2018","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.amjmed.2026.06.038_bib0010","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jacc.2025.06.012","article-title":"Aldosterone and Aldosterone modulation in cardio-kidney diseases","volume":"86","author":"Fioretti","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.amjmed.2026.06.038_bib0011","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jacc.2024.09.004","article-title":"Finerenone in patients with a recent worsening heart failure event: the FINEARTS-HF trial","volume":"85","author":"Desai","year":"2025","journal-title":"J Am Coll Cardiol"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326005152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326005152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:14:14Z","timestamp":1790846054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934326005152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0002934326005152"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.06.038","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid antagonists for post-MI HFpEF: Plausible biology meets low residual risk?","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.06.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}